查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1179952

2023-2030 年全球基底细胞癌治疗市场

Global Basal Cell Carcinoma Treatment Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

在预测期内 (2023-2030)，全球基底细胞癌治疗市场规模预计将以 9.4% 的复合年增长率增长。

基底细胞癌 (BCC) 是一种皮肤癌。 基底细胞癌是基底细胞癌的起点，基底细胞癌是一种皮肤细胞，当旧细胞退化时会产生新的皮肤细胞。 它可以有多种形式，但最常见的是皮肤上的半透明小肿块。 此外，它更容易发生在头部和颈部等阳光照射部位，发病率往往高于其他皮肤部位。

市场动态

推动全球基底细胞癌治疗市场的主要因素是随着皮肤癌的流行和基底细胞癌治疗产品的批准，预计市场将扩大。 人们越来越注重健康，这推动了市场的增长。

基底细胞癌治疗产品的批准有望推动市场增长。

角质形成细胞肿瘤（俗称非黑色素瘤皮肤恶性肿瘤）的发病率在世界范围内呈上升趋势，基底细胞癌和鳞状细胞癌是最常见的类型。 所有类型的癌症都需要手术，但有些病例会进展或转移，需要靶向治疗。 基底细胞癌受hedgehog信号系统的影响很大，其抑制是局部晚期和转移性基底细胞癌新疗法的关键。 使用 FDA 批准的药物进行的临床前和临床研究提出了化学预防和治疗基底细胞瘤的新应用。 此外，阻断 Hh 通路的新型化合物显示出前景，并与其他药物联合使用，可能为这种最常见的恶性肿瘤提供非手术治疗。

市场上的主要参与者正集中精力获得治疗基底细胞癌的产品批准，这将在预测期内推动全球基底细胞癌市场的增长。然后预测。 例如，2021年6月，欧盟委员会（EC）对总部位于巴黎的法国跨国製药公司赛诺菲（Sanofi）进行刺猬通路抑製剂（HHI）批准使用再生元（Regeneron）的PD-1抑製剂ribtayo (cemiplimab) 用于治疗患有或耐受性差的局部晚期或转移性基底细胞癌 (BCC) 的成人。

预计熟练专业人员的短缺会阻碍市场增长。

在预测期内，全球基底细胞癌治疗市场的发展可能会受到对不了解该疾病可用治疗方案的更多熟练专业人员的需求的限制。

COVID-19 影响分析

全球基底细胞癌治疗市场已受到 COVID-19 的不利影响。 越来越多的癌症患者对诊断数量产生了负面影响，并因此阻碍了世界治疗。 特别是在大流行初期，由于医疗机构高度重视遏制 COVID-19 大流行，新病例发现减少，诊断程序数量显着减少，皮肤病变活检等程序减少。 .

此外，COVID-19 疫情在许多方面给全球基底细胞癌市场的行业参与者带来严峻挑战。 运输不规范造成的最大问题之一是製造药物配方所需原材料的可用性。 此外，由于患有 COVID-19 和其他危及生命的疾病的患者数量不断增加，分销商正目睹零售商对其产品的不可预测的需求。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 司机
      • 市场预计会因皮肤癌的增加而扩大
      • 用于治疗基底细胞癌的产品获批
    • 约束因素
      • 缺乏熟练的专业人员，这是一个市场瓶颈
    • 商机
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 定价分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按治疗类型分类

  • 手术治疗
    • 手术切除
    • 电抛光/切割 ED&C
    • 莫氏手术和冷冻手术
  • 药物治疗
      • 局部治疗
      • 高级药物
      • 其他
  • 治愈
      • 放射治疗
      • 光动力疗法
      • 激光治疗

最终用户第 8 章

  • 医院
  • 专科诊所
  • 其他

第9章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第10章竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 产品基准
  • 值得关注的主要公司名单

第11章公司简介

  • Sun Pharmaceutical Industries, Inc
    • 公司简介
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • Sun Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Valeant Pharmaceuticals International, Inc.
  • Regeneron Pharmaceuticals Inc
  • Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Perrigo Company
  • Strides Arcolab Ltd
  • AiViva Bio Pharma, Inc
  • Sanofi

第 12 章全球基底细胞癌治疗市场-DataM

简介目录
Product Code: DMPH11

Market Overview

The global basal cell carcinoma treatment market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 9.4% during the forecast period (2023-2030).

Basal cell carcinoma (BCC) is a type of skin cancer. Basal cells, a type of skin cell that creates new skin cells as old ones degenerate, are where basal cell cancer starts. Although it can take numerous forms, basal cell carcinoma frequently manifests as a small, slightly translucent lump on the skin. The skin on the head and neck, as well as other sun-exposed locations, tends to develop basal cell carcinoma more frequently than other skin types.

Market Dynamics

The major factors driving the global basal cell carcinoma treatment market are the market is predicted to grow as skin cancers become more common and product approval for basal cell carcinoma therapy. People are becoming more mindful of their health, which helps the market grow.

Product approval for basal cell carcinoma therapy is expected to drive the market's growth.

The frequency of keratinocyte tumors, commonly known as non-melanoma skin malignancies, is rising worldwide, with basal cell carcinoma and squamous cell carcinoma being the most prevalent types. Even though surgery is the preferred course of action for both cancers, some cases can proceed to an advanced or metastatic stage, necessitating targeted therapy. The hedgehog signaling system heavily influences basal cell carcinoma, and its suppression is the key to new therapeutic approaches for both locally progressed and metastatic basal cell carcinoma. Preclinical and clinical research using already FDA-approved medications point to new applications for BCC chemoprevention and therapy. Additionally, novel chemical compounds that block the Hh pathway exhibit promise and may offer a nonsurgical treatment for this most prevalent malignancy when combined with other medications.

Then, the major players in the market are concentrating on getting their products approved for the treatment of basal cell carcinoma, which is anticipated to propel the growth of the global basal cell carcinoma market during the forecast period. For instance, in June 2021, The European Commission (EC) authorized Sanofi, a French multinational pharmaceutical company with its headquarters in Paris, to use Regeneron's PD-1 inhibitor Libtayo (cemiplimab) to treat adults with locally advanced or metastatic basal cell carcinoma (BCC) who have progressed on or become intolerable to a hedgehog pathway inhibitor (HHI).

Lack of skilled experts is expected to hamper the market's growth.

The development of the global basal cell carcinoma treatment market over the forecast period may be constrained by a need for more skilled experts who are ignorant of the available treatment options for this illness.

COVID-19 Impact Analysis

The global market for basal cell carcinoma therapeutics was adversely affected by the COVID-19. The increase in cancer cases had a negative impact on the number of diagnoses and thus hindered global Therapy. The discovery of new cases decreased, especially during the early stages of the pandemic, due to the healthcare systems' strong concentration on controlling the COVID-19 pandemic, a considerable drop in the number of diagnostic procedures, and a dip in procedures such as skin lesion biopsies.

Additionally, the COVID-19 pandemic is providing serious challenges for industry players in the global basal cell carcinoma market on a number of fronts. One of the biggest problems caused by transportation irregularities is the availability of raw materials required to produce pharmaceutical formulations. Additionally, due of an increase in patients with COVID-19 and other life-threatening disorders, distributors are witnessing unpredictable demand for their products from retailers.

Segment Analysis

The surgical excision segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The treatment segment is the highest market holder in the global basal cell carcinoma treatment market. Surgical excision is the most widely utilized treatment for basal cell carcinoma. The surgeon removes the malignant tumor together with a margin of good skin during this surgery. To ensure no cancer cells are present, the surplus is examined using a microscope. For basal cell carcinomas that are less prone to recur, such as those that develop on the chest, back, hands, and feet, excision may be advised.

Due to its lowest possible recurrence rates, highest possible cure rates, and best cosmetic outcomes among all treatment approaches for basal cell carcinoma, and surgical excision has proven to be more effective, leading to its high demand. Surgical removal with a 2-3-mm excision margin is an appropriate treatment with a 99% removal success rate for well-defined, primary-pigmented BCC.

The most popular kinds of skin cancer, basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs), are frequently treated with Mohs surgery. The process, known as Mohs micrographic surgery, is carried out in phases while the patient waits and includes lab testing. All malignant cells can be removed while sparing healthy tissue and leaving the lowest scar feasible to maximize the chance of curing cancer. Out of all available treatments, Mohs micrographic surgery has the highest success rate in curing basal cell and squamous cell skin malignancies. The cure rate for basal cell carcinoma is up to 99% for newly diagnosed patients and up to 94% for recurring cases. Over the next few, it is anticipated that surgical excision, followed by Mohs micrographic, will continue to dominate, reiterating the surgical segment's predominance.

Geographical Analysis

North America holds the largest market share in the global Basal Cell Carcinoma Treatment market.

North America dominates the global basal cell carcinoma treatment market primarily due to its large population, excellent medical infrastructure, and high-income levels. North America is anticipated to dominate the basal cell carcinoma treatment market throughout the forecast period. This is because of the rising incidence of the elderly population, increased knowledge of cutting-edge treatments, a favorable reimbursement environment, and the high frequency of basal cell carcinoma in this area.

According to the Centers for Disease Control and Prevention (CDC), there will be 3 to 4 million cases of non-melanoma skin cancer in the United States in 2020. This contributes to a larger patient base that needs the treatment. More individuals need medicine due to the rising prevalence of advanced basal cell carcinoma and Squamous cell carcinoma instances. Additionally, the region's growth is fueled by an increase in the number of new pharmaceuticals in the U.S. receiving regulatory approval.

For instance, in February 2021, As the first immunotherapy for patients with advanced basal cell carcinoma (BCC) who have not previously received a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate, the PD-1 inhibitor Libtayo (cemiplimab-rwlc) got FDA approval. Patients with locally advanced BCC received full approval, whereas those with metastatic BCC received accelerated approval. Additionally, the fact that Genetech and AiViva Biopharma International are conducting clinical trials to create novel therapeutics for basal cell carcinoma is likely to lead to an increase in the number of new product launches in the near term, which is also anticipated to fuel market growth.

Competitive Landscape

The Basal Cell Carcinoma Treatment market is moderately competitive with local and global companies' presence Sun Pharmaceuticals Ltd., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., Regeneron Pharmaceuticals Inc, Hoffmann-La Roche Ltd., Mylan N.V., Perrigo Company, Strides Arcolab Ltd, AiViva Bio Pharma, Inc and Allergan Inc

The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in December 2022, in a Phase I/II study to assess the safety and effectiveness of MW005 in the treatment of low-risk basal cell carcinoma, MediWound Ltd, a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today reported encouraging results (BCC).

Sun Pharmaceutical Industries, Inc.

Overview: An extensive selection of pharmaceutical formulations, including branded generics and generic medications, are offered by Sun Pharmaceutical Industries Ltd. (Sun Pharma), a speciality pharmaceutical company. Products for the treatment of psychiatric, neurological, nephrological, gastroenterological, orthopedic, and ophthalmologic diseases and disorders, as well as cardiac problems, are part of the company's portfolio.

Product Portfolio:

ODOMZO: It is a (sonidegib) is a prescription medicine used to treat adults with a type of skin cancer, called basal cell carcinoma, that has come back following surgery or radiation or that cannot be treated with surgery or radiation..

The global Basal Cell Carcinoma Treatment market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The market is predicted to grow as skin cancers become more common
      • 4.1.1.2. Product approval for basal cell carcinoma therapy
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of skilled experts, that which hampers the market
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis
  • 5.4 Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.1.2. Market Attractiveness Index, By Treatment Type
  • 7.2. Surgical
      • 7.2.1.1. Surgical Excision
      • 7.2.1.2. Electrodessication & Cutterage ED&C
      • 7.2.1.3. Moh's Surgery and Cryosurgery
    • 7.2.2. Introduction
    • 7.2.3. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Drugs
      • 7.3.1.1. Topical Treatment
      • 7.3.1.2. Advanced Medication
      • 7.3.1.3. Others
  • 7.4. Therapy
      • 7.4.1.1. Radiation Therapy
      • 7.4.1.2. Photodynamic Therapy
      • 7.4.1.3. Laser Therapy

8. By End user

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 8.1.2. Market Attractiveness Index, By End user
  • 8.2. Hospitals
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Specialty Clinics
  • 8.4. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user

10. Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Products Benchmarking
  • 10.4. List of Key Companies to Watch

11. Company Profiles

  • 11.1. Sun Pharmaceutical Industries, Inc
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Sun Pharmaceuticals Ltd.
  • 11.3. Merck & Co., Inc.
  • 11.4. Valeant Pharmaceuticals International, Inc.
  • 11.5. Regeneron Pharmaceuticals Inc
  • 11.6. Hoffmann-La Roche Ltd.
  • 11.7. Mylan N.V.
  • 11.8. Perrigo Company
  • 11.9. Strides Arcolab Ltd
  • 11.10. AiViva Bio Pharma, Inc
  • 11.11. Sanofi

LIST NOT EXHAUSTIVE

12. Global Basal Cell Carcinoma Treatment Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and Application
  • 12.3. Contact Us